Mon, October 10, 2011
[ Mon, Oct 10th 2011 ]: Market Wire
The Samsung Stratospherea"
Sun, October 9, 2011
Sat, October 8, 2011
[ Sat, Oct 08th 2011 ]: Market Wire
00 p.m. ET
Fri, October 7, 2011
Thu, October 6, 2011
[ Thu, Oct 06th 2011 ]: Market Wire
Quarterly Operational Update
Wed, October 5, 2011
Tue, October 4, 2011
Mon, October 3, 2011
Sun, October 2, 2011
Sat, October 1, 2011
Fri, September 30, 2011
Thu, September 29, 2011
Wed, September 28, 2011
Tue, September 27, 2011
Mon, September 26, 2011
Sat, September 24, 2011
Fri, September 23, 2011
[ Fri, Sep 23rd 2011 ]: Market Wire
????????????????????
Thu, September 22, 2011

Transgenomic to Present at the Craig-Hallum 2nd Annual Alpha Select Conference


  Copy link into your clipboard //science-technology.news-articles.net/content/2 .. g-hallum-2nd-annual-alpha-select-conference.html
  Print publication without navigation Published in Science and Technology on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

OMAHA, Neb.--([ BUSINESS WIRE ])--Transgenomic, Inc. (OTCBB: TBIO) today announced that Chad Richards, Chief Commercial Officer of Transgenomic, will be presenting at the Craig-Hallum Capital Groupa™s 2011 Alpha Select Investor Conference on Thursday, October 6th at 9:20 AM Eastern Time at The Roosevelt Hotel in New York City.

The presentation will be webcast live at [ http://wsw.com/webcast/ch/tbio.ob/ ]and is available for viewing at the Companya™s web site at [ http://www.transgenomic.com/events.asp?id=6 ], where it will be archived for 90 days.

About Transgenomic

Transgenomic, Inc. ([ www.transgenomic.com ]) is a global biotechnology company advancing personalized medicine in cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. The Company has three complementary business divisions: Transgenomic Pharmacogenomic Services is a contract research laboratory that specializes in supporting all phases of pre-clinical and clinical trials for oncology drugs in development. Transgenomic Clinical Laboratories specializes in molecular diagnostics for cardiology, neurology, mitochondrial disorders, and oncology. Transgenomic Diagnostic Tools produces equipment, reagents, and other consumables that empower clinical and research applications in molecular testing and cytogenetics. Transgenomic believes there is significant opportunity for continued growth across all three businesses by leveraging their synergistic capabilities, technologies, and expertise. The Company actively develops and acquires new technology and other intellectual property that strengthen its leadership in personalized medicine.


Publication Contributing Sources